Press Releases
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale,
commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.
Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics’ facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.
“This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,” said John Rim, CEO of Samsung Biologics. “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”
“We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the U.S.,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “We and our manufacturing partners remain committed to defeating the COVID-19 pandemic.”
Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale,commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.
Upon execution of the deal, technology transfer will commenceimmediately at Samsung Biologics’ facilities in Incheon, South Korea, utilizinga state-of-the-art production line equipped for aseptic fill-finish, labeling,and packaging services to support the production of hundreds of millions ofdoses of Moderna’s COVID-19 vaccine intended for the supply of markets outsideof the U.S. starting in the third quarter of 2021.
“This vaccine is paramount to people around the world in thefight against the COVID-19 pandemic, and we truly appreciate our client Modernafor entrusting and choosing to partner with Samsung Biologics for the fill andfinish of this important vaccine,” said John Rim, CEO of Samsung Biologics.“Due to the high level of urgency in supplying the vaccine to the globalpopulation, we have set immediate action plans and schedule to make mRNA-1273available for commercial distribution in the early second half of 2021.”
“We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the U.S.,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “We and our manufacturing partnersremain committed to defeating the COVID-19 pandemic.”